texas oncology more breakthroughs. more victories



Habte Yimer, MD, Considers the Outcomes of the GRIFFIN Study in Multiple Myeloma

Publication: Oncology Business Review

Habte Yimer, hematologist and medical oncologist with Texas Oncology–Tyler, discusses the outcomes of the GRIFFIN study, a phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma patients.
Click here to watch the full story.

Related Physicians

Related Cancer Centers